{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:04:09Z","timestamp":1792415049362,"version":"4.4.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","surveyophthalmol.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.survophthal.2024.09.011","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T15:54:33Z","timestamp":1728143673000},"page":"86-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Choroidal thickness after anti-vascular endothelial growth factor in typical neovascular age-related macular degeneration \u2013 A systematic review and meta-analysis"],"prefix":"10.1016","volume":"70","author":[{"given":"Erlend","family":"Hoven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Thomas","family":"Michelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario V.","family":"Vettore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Lagali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2024.09.011_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/srep21090","article-title":"Choroidal vascularity index as a measure of vascular status of the choroid: measurements in healthy eyes from a population-based study","volume":"6","author":"Agrawal","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.survophthal.2024.09.011_bib2","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.2147\/OPTH.S334619","article-title":"Regional distribution of choroidal thickness and diurnal variation in choroidal thickness and axial length in young adults","volume":"15","author":"Alanazi","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.09.011_bib3","article-title":"Long-term effect of intravitreal aflibercept treatment on choroidal vascularity index in neovascular age-related macular degeneration","volume":"36","author":"Alis","year":"2021","journal-title":"Photo Photo Ther"},{"issue":"7","key":"10.1016\/j.survophthal.2024.09.011_bib4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/08820538.2021.1903944","article-title":"Quantitative analysis of the activity in choroidal neovascularizations after a single anti-VEGF injection: OCT versus OCT angiography","volume":"36","author":"Altinisik","year":"2021","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2024.09.011_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10384-021-00894-w","article-title":"Assessment of choriocapillaris\/Sattler and Haller layer changes after intravitreal injection in eyes with neovascular age-related macular degeneration: aflibercept vs ranibizumab","volume":"66","author":"Altunel","year":"2022","journal-title":"Jpn J Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2024.09.011_bib6","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/IAE.0000000000002582","article-title":"Efficacy and safety of a treat-and-extend regimen with aflibercept in treatment-naive patients with type 3 neovascularization: a 52-Week, Single-Arm, Multicenter Trial","volume":"40","author":"Arias","year":"2020","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.survophthal.2024.09.011_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jfo.2018.01.005","article-title":"Two year outcome in treatment-naive patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept","volume":"41","author":"Barakat","year":"2018","journal-title":"J Fr Ophtalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2024.09.011_bib8","first-page":"494","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials","volume":"21","author":"Barker","year":"2023","journal-title":"JBI Evid Synth"},{"issue":"5","key":"10.1016\/j.survophthal.2024.09.011_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamaophthalmol.2013.692","article-title":"Effect of intravitreous anti-vascular endothelial growth factor therapy on choroidal thickness in neovascular age-related macular degeneration using spectral-domain optical coherence tomography","volume":"131","author":"Branchini","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.09.011_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-03179-x","article-title":"Short-term changes in retinal and choroidal relative flow volume after anti-VEGF treatment for neovascular age-related macular degeneration","volume":"11","author":"Calzetti","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.survophthal.2024.09.011_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40123-019-00221-0","article-title":"Prospective study of vessel density by optical coherence tomography angiography after intravitreal bevacizumab in exudative age-related macular degeneration","volume":"9","author":"Cennamo","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"9900","key":"10.1016\/j.survophthal.2024.09.011_bib12","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.survophthal.2024.09.011_bib13","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.2147\/OPTH.S285257","article-title":"Effects of intravitreous aflibercept injection in pachychoroid neovasculopathy: comparison with typical neovascular age-related macular degeneration","volume":"15","author":"Elfandi","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.09.011_bib14","first-page":"837","article-title":"Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization","volume":"6","author":"Ellabban","year":"2012","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2024.09.011_bib15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00417-017-3888-2","article-title":"Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial","volume":"256","author":"Fan","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.09.011_bib16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4103\/jovr.jovr_125_18","article-title":"Role of the choroid in age-related macular degeneration: a current review","volume":"14","author":"Farazdaghi","year":"2019","journal-title":"J Ophthalmic Vis Res"},{"issue":"8","key":"10.1016\/j.survophthal.2024.09.011_bib17","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.survophthal.2024.09.011_bib18","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.1941.00870100042005","article-title":"Prevalence of age-related macular degeneration in the United States","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2024.09.011_bib19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/02713683.2017.1405045","article-title":"Comparison of short-term choroidal thickness and retinal morphological changes after intravitreal Anti-VEGF therapy with ranibizumab or aflibercept in treatment-naive eyes","volume":"43","author":"Gharbiya","year":"2018","journal-title":"Curr Eye Res"},{"issue":"1","key":"10.1016\/j.survophthal.2024.09.011_bib20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2024.09.011_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/15569527.2022.2034843","article-title":"Retinal nerve fibre layer and ganglion cell layer thickness changes following intravitreal aflibercept for age-related macular degeneration","volume":"41","author":"Gunay","year":"2022","journal-title":"Cutan Ocul Toxicol"},{"issue":"11","key":"10.1016\/j.survophthal.2024.09.011_bib22","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.survophthal.2024.09.011_bib23","unstructured":"Higgins J.P.T.T.J., Chandler J., Cumpston M., Li T., Page M.J., Welch V.A. (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org\/handbook. 2022."},{"issue":"1","key":"10.1016\/j.survophthal.2024.09.011_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40123-019-00227-8","article-title":"A review of macular atrophy of the retinal pigment epithelium in patients with neovascular age-related macular degeneration: what is the link? Part II","volume":"9","author":"Horani","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"10.1016\/j.survophthal.2024.09.011_bib25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods"},{"issue":"1","key":"10.1016\/j.survophthal.2024.09.011_bib26","first-page":"94","article-title":"Past, Present, and future concepts of the choroidal scleral interface morphology on optical coherence tomography","volume":"6","author":"Huynh","year":"2017","journal-title":"Asia Pac J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2024.09.011_bib27","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1080\/02713683.2019.1600195","article-title":"Long-term changes in submacular choroidal thickness after intravitreal ranibizumab therapy for neovascular age-related macular degeneration: 14-Mo follow-up","volume":"44","author":"Inan","year":"2019","journal-title":"Curr Eye Res"},{"issue":"5","key":"10.1016\/j.survophthal.2024.09.011_bib28","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s40123-023-00779-w","article-title":"Visual and anatomical outcomes after initial intravitreal faricimab injection for neovascular age-related macular degeneration in patients with prior treatment history","volume":"12","author":"Inoda","year":"2023","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"10.1016\/j.survophthal.2024.09.011_bib29","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000479937","article-title":"Two-year outcomes of a treat-and-extend regimen using intravitreal aflibercept injections for typical age-related macular degeneration","volume":"238","author":"Ito","year":"2017","journal-title":"Ophthalmologica"},{"issue":"3","key":"10.1016\/j.survophthal.2024.09.011_bib30","article-title":"Choroidal thickness changes in patients with wet age-related macular degeneration over one year of aflibercept treatment","volume":"121","author":"Jamio\u0142kowska","year":"2019","journal-title":"Klin Ocz"},{"issue":"6","key":"10.1016\/j.survophthal.2024.09.011_bib31","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/bjophthalmol-2013-304019","article-title":"Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes","volume":"98","author":"Julien","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2024.09.011_bib32","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ajo.2014.01.019","article-title":"Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration","volume":"157","author":"Kang","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.09.011_bib33","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.2147\/OPTH.S90932","article-title":"Foveal structure during the induction phase of anti-vascular endothelial growth factor therapy for occult choroidal neovascularization in age-related macular degeneration","volume":"9","author":"Kano","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2024.09.011_bib34","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jfo.2017.04.014","article-title":"Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: ranibizumab versus aflibercept","volume":"40","author":"Kaya","year":"2017","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.survophthal.2024.09.011_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/srep44020","article-title":"Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration","volume":"7","author":"Kikushima","year":"2017","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.survophthal.2024.09.011_bib36","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/bjophthalmol-2015-308074","article-title":"Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study","volume":"100","author":"Kim","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2024.09.011_bib37","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","article-title":"A brief history of anti-VEGF for the treatment of ocular angiogenesis","volume":"181","author":"Kim","year":"2012","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.survophthal.2024.09.011_bib38","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/IAE.0000000000000952","article-title":"Choroidal thickness change after intravitreal anti-vascular endothelial growth factor treatment in retinal angiomatous proliferation and its recurrence","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.survophthal.2024.09.011_bib39","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1111\/aos.13399","article-title":"Choroidal vascular changes in age-related macular degeneration","volume":"95","author":"Koh","year":"2017","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2024.09.011_bib40","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ajo.2014.12.025","article-title":"Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration","volume":"159","author":"Koizumi","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2024.09.011_bib41","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00417-011-1620-1","article-title":"Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"249","author":"Koizumi","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2024.09.011_bib42","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/bjophthalmol-2018-312625","article-title":"Subfoveal choroidal thickness as a prognostic factor in exudative age-related macular degeneration","volume":"103","author":"Kumar","year":"2019","journal-title":"Brit J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2024.09.011_bib43","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ajo.2008.12.008","article-title":"A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes","volume":"147","author":"Margolis","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2024.09.011_bib44","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1007\/s00417-023-06116-y","article-title":"Short-term outcomes of intravitreal faricimab for treatment-naive neovascular age-related macular degeneration","volume":"261","author":"Matsumoto","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2024.09.011_bib45","first-page":"2282","article-title":"Treat-and-extend regimen with aflibercept for retinal angiomatous proliferation","volume":"36","author":"Matsumoto","year":"2016","journal-title":"Retin J Ret Vit Dis"},{"issue":"10","key":"10.1016\/j.survophthal.2024.09.011_bib46","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/bjophthalmol-2015-306636","article-title":"Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration","volume":"99","author":"Mazaraki","year":"2015","journal-title":"Brit J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.09.011_bib47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"issue":"7","key":"10.1016\/j.survophthal.2024.09.011_bib48","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1007\/s12325-022-02129-x","article-title":"Choroidal thickness changes after intravitreal aflibercept injections in treatment-naive neovascular AMD","volume":"39","author":"Minnella","year":"2022","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.survophthal.2024.09.011_bib49","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40259-016-0179-0","article-title":"Choroidal thickness changes after intravitreal ranibizumab for exudative age-related macular degeneration","volume":"30","author":"Minnella","year":"2016","journal-title":"Biodrugs"},{"key":"10.1016\/j.survophthal.2024.09.011_bib50","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"1-2","key":"10.1016\/j.survophthal.2024.09.011_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000468950","article-title":"Comparison of pro re nata versus bimonthly injection of intravitreal aflibercept for typical neovascular age-related macular degeneration","volume":"238","author":"Mori","year":"2017","journal-title":"Ophthalmologica"},{"issue":"1","key":"10.1016\/j.survophthal.2024.09.011_bib52","doi-asserted-by":"crossref","first-page":"8747","DOI":"10.1038\/s41598-023-35759-4","article-title":"Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan","volume":"13","author":"Mukai","year":"2023","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.survophthal.2024.09.011_bib53","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"4","key":"10.1016\/j.survophthal.2024.09.011_bib54","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00417-016-3507-7","article-title":"A modified treat-and-extend regimen of aflibercept for treatment-naive patients with neovascular age-related macular degeneration","volume":"255","author":"Ohnaka","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.09.011_bib55","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"issue":"12","key":"10.1016\/j.survophthal.2024.09.011_bib56","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1097\/IAE.0000000000001480","article-title":"Macular choroidal volume changes after intravitreal bevacizumab for exudative age-related macular degeneration","volume":"37","author":"Palkovits","year":"2017","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.survophthal.2024.09.011_bib57","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"issue":"4","key":"10.1016\/j.survophthal.2024.09.011_bib58","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00417-020-04957-5","article-title":"Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration","volume":"259","author":"Pellegrini","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2024.09.011_bib59","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ajo.2015.08.009","article-title":"Assessment of choroidal topographic changes by swept-source optical coherence tomography after intravitreal ranibizumab for exudative age-related macular degeneration","volume":"160","author":"Razavi","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2024.09.011_bib60","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","article-title":"Interpretation of subgroup analyses in systematic reviews: a tutorial","volume":"7","author":"Richardson","year":"2019","journal-title":"Clin Epidemiol Glob"},{"issue":"1","key":"10.1016\/j.survophthal.2024.09.011_bib61","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.survophthal.2022.07.006","article-title":"Retinal and choroidal changes in AMD: a systematic review and meta-analysis of spectral-domain optical coherence tomography studies","volume":"68","author":"Salehi","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.09.011_bib62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inf Decis Mak"},{"issue":"1","key":"10.1016\/j.survophthal.2024.09.011_bib63","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/08164622.2021.1896334","article-title":"Comparison of intravitreal injections of Ranibizumab and Aflibercept in neovascular age related macular degeneration","volume":"105","author":"Sizmaz","year":"2022","journal-title":"Clin Exp Optom"},{"issue":"6","key":"10.1016\/j.survophthal.2024.09.011_bib64","doi-asserted-by":"crossref","first-page":"904","DOI":"10.5301\/ejo.5000478","article-title":"Retinal and choroidal thickness changes after single anti-VEGF injection in neovascular age-related macular degeneration: ranibizumab vs bevacizumab","volume":"24","author":"Sizmaz","year":"2014","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2024.09.011_bib65","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1167\/iovs.14-14447","article-title":"Choroidal structure in normal eyes and after photodynamic therapy determined by binarization of optical coherence tomographic images","volume":"55","author":"Sonoda","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2024.09.011_bib66","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajo.2015.04.012","article-title":"Optical coherence tomography angiography signs of vascular abnormalization with antiangiogenic therapy for choroidal neovascularization","volume":"160","author":"Spaide","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2024.09.011_bib67","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2024.09.011_bib68","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000513048","article-title":"Brolucizumab: a newly developed Anti-VEGF molecule for the treatment of neovascular age-related macular degeneration","volume":"244","author":"Tadayoni","year":"2021","journal-title":"Ophthalmologica"},{"issue":"6","key":"10.1016\/j.survophthal.2024.09.011_bib69","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00417-021-05517-1","article-title":"Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study","volume":"260","author":"Tamashiro","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2024.09.011_bib70","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.18240\/ijo.2021.08.12","article-title":"N. Choroidal structural changes determined by the binarization method after intravitreal aflibercept treatment in neovascular age-related macular degeneration","volume":"14","author":"Temel","year":"2021","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.09.011_bib71","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/15569527.2017.1354217","article-title":"Retrospective analysis of the effect of aflibercept loading dose on the retinal vessel diameters in patients with treatment-naive neovascular AMD","volume":"37","author":"Tetikoglu","year":"2018","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.survophthal.2024.09.011_bib72","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ajo.2015.12.024","article-title":"Choroidal thickness changes in age-related macular degeneration and polypoidal choroidal vasculopathy: a 12-month prospective study","volume":"164","author":"Ting","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.09.011_bib73","article-title":"Brolucizumab intravitreal injection in macular neovascularization type 1: VA, SD-OCT and OCTA parameters changes during a 16-weeks follow up","author":"Toto","year":"2022","journal-title":"Ophthalmic Res"},{"issue":"1","key":"10.1016\/j.survophthal.2024.09.011_bib74","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10792-016-0242-3","article-title":"Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema","volume":"37","author":"Unlu","year":"2017","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.09.011_bib75","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ajo.2016.06.023","article-title":"Repeatability of choroidal thickness measurements on enhanced depth imaging optical coherence tomography using different posterior boundaries","volume":"169","author":"Vuong","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.09.011_bib76","article-title":"The application of enhanced depth imaging spectral-domain optical coherence tomography in macular diseases","volume":"2020","author":"Wang","year":"2020","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.09.011_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.783519","article-title":"Evaluation of choroidal thickness using optical coherent tomography: a review","volume":"8","author":"Xie","year":"2021","journal-title":"Front Med"},{"issue":"9","key":"10.1016\/j.survophthal.2024.09.011_bib78","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00417-015-3260-3","article-title":"Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration","volume":"254","author":"Yun","year":"2016","journal-title":"Graef Arch Clin Exp"},{"key":"10.1016\/j.survophthal.2024.09.011_bib79","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12886-016-0203-7","article-title":"Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration","volume":"16","author":"Yun","year":"2016","journal-title":"BMC Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2024.09.011_bib80","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/IAE.0000000000001360","article-title":"Effect of intravitreal ranibizumab on ganglion cell complex and peripapillary retinal nerve fiber layer in neovascular age-related macular degeneration using spectral domain optical coherence tomography","volume":"37","author":"Zucchiatti","year":"2017","journal-title":"Retina"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625724001243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625724001243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T05:04:50Z","timestamp":1732856690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625724001243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0039625724001243"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2024.09.011","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Choroidal thickness after anti-vascular endothelial growth factor in typical neovascular age-related macular degeneration \u2013 A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2024.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}